Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,441 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.
Santini D, Pantano F, Riccardi F, Di Costanzo GG, Addeo R, Guida FM, Ceruso MS, Barni S, Bertocchi P, Marinelli S, Marchetti P, Russo A, Scartozzi M, Faloppi L, Santoni M, Cascinu S, Maiello E, Silvestris F, Tucci M, Ibrahim T, Masi G, Gnoni A, Comandone A, Fazio N, Conti A, Imarisio I, Pisconti S, Giommoni E, Cinieri S, Catalano V, Palmieri VO, Infante G, Aieta M, Trogu A, Gadaleta CD, Brunetti AE, Lorusso V, Silvestris N. Santini D, et al. Among authors: marchetti p. PLoS One. 2014 Aug 29;9(8):e105268. doi: 10.1371/journal.pone.0105268. eCollection 2014. PLoS One. 2014. PMID: 25170882 Free PMC article.
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review.
Airoldi M, Amadori D, Barni S, Cinieri S, De Placido S, Di Leo A, Gennari A, Iacobelli S, Ionta MT, Lorusso V, Lotrionte M, Marchetti P, Mattioli R, Minotti G, Pronzato P, Rosti G, Tondini CA, Veronesi A. Airoldi M, et al. Among authors: marchetti p. Tumori. 2011 Nov-Dec;97(6):690-2. doi: 10.1177/030089161109700602. Tumori. 2011. PMID: 22322832 Review.
Premetastatic niche: ready for new therapeutic interventions?
Zoccoli A, Iuliani M, Pantano F, Imperatori M, Intagliata S, Vincenzi B, Marchetti P, Papapietro N, Denaro V, Tonini G, Santini D. Zoccoli A, et al. Among authors: marchetti p. Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S119-29. doi: 10.1517/14728222.2012.656092. Epub 2012 Mar 23. Expert Opin Ther Targets. 2012. PMID: 22443277 Review.
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.
Gridelli C, de Marinis F, Ardizzoni A, Novello S, Fontanini G, Cappuzzo F, Grossi F, Santo A, Cortinovis D, Favaretto A, Lorusso V, Galetta D, Siena S, Bettini A, Iurlaro M, Caprioli A; LIFE study team. Gridelli C, et al. J Cancer Res Clin Oncol. 2014 Oct;140(10):1783-93. doi: 10.1007/s00432-014-1715-2. Epub 2014 Jun 6. J Cancer Res Clin Oncol. 2014. PMID: 24903964 Free article.
Italian Oncological Pain Survey (IOPS): a multicentre Italian study of breakthrough pain performed in different settings.
Mercadante S, Lazzari M, Reale C, Cuomo A, Fusco F, Marchetti P, Mediati RD, Chiurazzi B, Ciuffedra L, Caraceni A, Iaffaioli V, Luzzani M, Micheletto G, Papa A, Raffaeli W, Valle A, Caruso M, Di Costanzo F, Pinato G, Nardi F, Barni S, Natoli S, Mammucari M, Sabato AF, Dauri M; IOPS Study Group. Mercadante S, et al. Among authors: marchetti p. Clin J Pain. 2015 Mar;31(3):214-21. doi: 10.1097/AJP.0000000000000161. Clin J Pain. 2015. PMID: 25654429
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.
Santini D, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Altobelli E, Biasco E, Ricotta R, Porta C, Vincenzi B, Papalia R, Marchetti P, Burattini L, Berardi R, Muto G, Montironi R, Cascinu S, Tonini G. Santini D, et al. Among authors: marchetti p. Oncotarget. 2016 May 31;7(22):33381-90. doi: 10.18632/oncotarget.8302. Oncotarget. 2016. PMID: 27027342 Free PMC article.
H2020 and Beyond: Skip Discrepancy between Theory and Practice of Personalized Medicine. A Position Paper by the Italian Society of Personalized Medicine.
Borro M, Simmaco M, Aceti A, Barni S, De Luca A, Fineschi V, Frati P, Girardi P, Miozzo M, Nati G, Nicoletti F, Santini D, Marchetti P. Borro M, et al. Among authors: marchetti p. Curr Pharm Biotechnol. 2016;17(10):926-9. doi: 10.2174/1389201017666160519112850. Curr Pharm Biotechnol. 2016. PMID: 27194357
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.
Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferraú F, Labianca R, Ronzoni M, Scartozzi M, Galli F; GISCAD investigators. Cascinu S, et al. Among authors: marchetti p. Eur J Cancer. 2017 Sep;83:106-115. doi: 10.1016/j.ejca.2017.06.029. Epub 2017 Jul 20. Eur J Cancer. 2017. PMID: 28735067 Clinical Trial.
1,441 results